- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06314828
A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL
A Phase 1, Open-label, Single Arm Clinical Trial to Evaluate the Tolerability, Safety and Efficacy of RJMty19 in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Weili Zhao, MD,PhD
- Phone Number: 610707 +862164370045
- Email: zhao.weili@yahoo.com
Study Contact Backup
- Name: Zixun Yan, MD,PhD
- Phone Number: 610707 +862164370045
- Email: yzx12119@rjh.com.cn
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntarily sign an ICF and expect to complete the subsequent follow-up.
- Aged 18 to 65 years (including cut-offs), regardless of gender.
- B-cell non-Hodgkin's lymphoma diagnosed as CD19-positive by cytology or histopathology according to WHO 2022 criteria, including pathologically confirmed (1) diffuse large B-cell lymphoma, non-specific type (DLBCL, NOS); (2) follicular lymphoma histopathologically graded as grade 3b (FL3b); (3) follicular lymphoma with diffuse large B-cell transformation; (4) primary mediastinal large B-cell lymphoma (PMBCL); (5) high-grade B-cell lymphoma (HGBCL).
Relapsed/refractory B-cell non-Hodgkin's lymphoma, provided one of the following conditions is met:
- Definition of relapse: Relapse after achieving remission (PR and CR) with second-line or higher therapy;
Definition of refractory:
- No response to second-line or more therapy: The best efficacy of last therapy is PD or SD (SD requires at least 2 cycles of treatment);
- Recurrence (must have biopsy-proven recurrence) or progression within 12 months of autologous stem cell transplantation (ASCT) . If salvage therapy, no response to last therapy (SD or PD).
Subjects must have received adequate treatment in the past, which should include the following treatments:
- Anti-CD20 monoclonal antibody, unless the investigator determines that the tumor is CD20 negative;
- Chemotherapy containing anthracycline drugs;
- For subjects with transformed follicular lymphoma (tFL) who have been previously treated with follicular lymphoma (FL) chemotherapy and with transformation to DLBCL show refractory to chemotherapy.
- ECOG performance status 0 to 1.
The presence of a measurable lesion that meets one of the following criteria:
- The long axis of the lymph node lesion exceeds 15 mm in length (the short axis is measurable);
- The long and short axes of the extralymph node lesion exceed 10 mm in length.
ALaboratory results within 7 days prior to Lymphodepletion need to meet the following criteria:
Coagulation function:
- Activated partial thromboplastin time ≤ 1.5 times the upper limit of normal (ULN);
- Prothrombin time (PT) ≤ 1.5 times ULN;
Liver function:
- Glutathione aminotransferase (AST) ≤ 5 times the upper limit of normal (ULN);
- Glutamic aminotransferase (ALT) ≤ 5 times the upper limit of normal (ULN);
- Total bilirubin ≤ 1.5 times ULN, unless the subject has documented Gilbert syndrome;
- Subjects with Gilbert-Meulengracht syndrome with total bilirubin ≤ 3.0 times ULN and direct bilirubin ≤ 1.5 times ULN may be included.
Renal function:
- Serum creatinine ≤ 1.5 times ULN or a creatinine clearance ≥ 60 ml/min;
Complete blood count (No blood transfusion treatment received within 7 days prior to examination):
- Haemoglobin ≥ 80 g/L;
- Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L;
- A platelet count ≥ 50 x 10^9/L;
Cardiopulmonary function:
- Left ventricular ejection fraction (LVEF) ≥ 45%;
- Oxygen saturation ≥ 91%;
Female subjects with of childbearing potential should have a negative pregnancy test during the screening period. Any male and female subjects of childbearing potential must agree to use an effective contraception method for at least six months from the time that they sign the informed consent form until the end of the cell infusion. Female subjects without childbearing potential (meeting at least 1 of the following criteria) is described below:
- Have undergone a hysterectomy or bilateral oophorectomy;
- Medically recognised ovarian failure;
- Medically recognised as post-menopausal (at least 12 consecutive months of menopause without pathological or physiological cause).
Exclusion Criteria:
- Other malignancies within 5 years prior to screening, except adequately treated carcinoma in situ of the cervix, basal cell or squamous epithelial cell skin cancer, post-radical localized prostate cancer, post-radical ductal carcinoma in situ, and post-radical thyroid cancer
- Any unstable systemic disease: including but not limited to active infection (other than local infection), unstable angina, cerebrovascular accident or transient ischaemia (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), New York Heart Association class III or IV cardiac insufficiency, refractory hypertension (refractory hypertension is defined as blood pressure that has not reached standard after >1 month of reasonably tolerable treatment with ≥3 antihypertensive drugs (including diuretics) at adequate doses based on lifestyle improvement or blood pressure that is not effectively controlled with ≥4 antihypertensive drugs), severe cardiac arrhythmias requiring pharmacologic treatment, hepatic arrhythmias, liver diseases, kidney diseases or metabolic disorders.
- Patients with B-cell non-Hodgkin's lymphoma with active central nervous system invasion.
- Patients with positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and peripheral blood hepatitis B virus (HBV) DNA titres not within the normal reference range, positive hepatitis C virus (HCV) antibody and peripheral blood HCV RNA ,positive for human immunodeficiency virus (HIV), or positive for cytomegalovirus (CMV) DNA, or positive syphilis test.
- Subjects who are receiving systemic steroids prior to screening and who are judged by the investigator to require long-term treatment with systemic steroids during the treatment period (except for inhaled or topical use).
- Previous organ transplantation or preparation for organ transplantation (except for haematopoietic stem cell transplantation).
- Persons with acute/chronic Graft-vs-Host Disease (GvHD).
- Patients have received a haematopoietic stem cell transplant within 2 months prior to screening.
- Active neurological autoimmune or inflammatory diseases (e.g. Guillain-Barre Syndrome (GBS), Amyotrophic lateral sclerosis (ALS)).
- Clinically significant active cerebrovascular diseases (such as cerebral edema, posterior reversible encephalopathy syndrome).
- Patients with a life expectancy of less than 3 months.
- Subjects have participated in other interventional clinical studies within 3 months prior to screening.
- Received attenuated live vaccine within 6 weeks prior to lymphodepletion.
- The subjects have contraindications or hypersensitivity reactions to fludarabine, cyclophosphamide, etoposide, tocilizumab, investigational product and its ingredients.
- Remaining within the washout period of other antitumor treatments prior to lymphodepletion.
- Patients who, in the investigator's judgment and/or clinical criteria, have a contraindication to any of the study procedures or have other medical conditions that may place them at unacceptable risk.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RJMty19 (CD19-CAR-DNT Cells)
The trial is divided into two parts: Part A is a dose escalation trial with four dose groups (5×10^6 CAR+ cells/kg, 1×10^7 CAR+ cells/kg, 2×10^7 CAR+ cells/kg and 4×10^7 CAR+ cells/kg at day 0), with 8-24 patients planned to be enrolled.
Part B is a dose-expansion trial in which 3~6 patients will receive RJMty19 infusions at RP2D dose levels.
|
Lentiviral vector-transducted double negative T cells (DNT) to express anti-CD19 CAR.
Prior to cellular infusion, each patient received cyclophosphamide, fludarabine and Etoposide lymphodepleting chemotherapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of abnormalities
Time Frame: Up to 28 days
|
Incidence of abnormalities in AE/SAE/AESI/laboratory tests/electrocardiograms/vital signs.
|
Up to 28 days
|
Dose-Limiting Toxicity (DLT)
Time Frame: Up to 28 days
|
To evaluate the safety, tolerability, and determine the recommended dosage of RJMty19 for R/R B-NHL subjects
|
Up to 28 days
|
Maximum Tolerated Dose (MTD)
Time Frame: Up to 28 days
|
MTD is the highest dose for DLT in ≤1/6 subjects
|
Up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate
Time Frame: Up to 2 years
|
The proportion of CR or PR patients as assessed by investigators based on Lugano 2014 Response Assessment
|
Up to 2 years
|
Disease Control Rate
Time Frame: Up to 2 years
|
The percentage of PR, CR and SD patients in the total patient population
|
Up to 2 years
|
Duration of Response
Time Frame: Up to 2 years
|
The time from the start of the first assessment of CR or PR to the first assessment as disease recurrence or progression or death
|
Up to 2 years
|
Overall Survival
Time Frame: Up to 15 years
|
From the date of entry into the clinical study until death from any cause
|
Up to 15 years
|
Pharmacokinetics (PK) indicator (Cmax)
Time Frame: Up to 90 days
|
The peak concentration of CD19-CAR-DNT cells amplified in the peripheral blood (Cmax, detected by qPCR and Flow Cytometry).
|
Up to 90 days
|
Pharmacokinetics (PK) indicator (AUC)
Time Frame: Up to 90 days
|
CD19-CAR-DNT cells blood concentrations will be measured at different time points to evaluate the area under the curve (AUC).
(AUC, detected by qPCR and Flow Cytometry).
|
Up to 90 days
|
Pharmacokinetics (PK) indicator (Tmax)
Time Frame: Up to 90 days
|
CD19-CAR-DNT cells blood concentrations will be measured at different time points to evaluate the peak plasma time (Tmax).
Tmax is defined as the time to reach the highest concentration (Tmax, detected by qPCR and Flow Cytometry).
|
Up to 90 days
|
Pharmacokinetics (PK) indicator (T1/2)
Time Frame: Up to 90 days
|
CD19-CAR-DNT cells blood concentrations will be measured at different time points to evaluate the elimination half-life in hours (T1/2).
T1/2 is defined as the time point when the concentration of CD19-CAR-DNT reaches half of maximum in a patient's peripheral blood (T1/2, detected by qPCR and Flow Cytometry).
|
Up to 90 days
|
Progression Free Survival
Time Frame: Up to 2 years
|
The length of time that a participant's disease did not progress during or after RJMty19 infusion.
|
Up to 2 years
|
Overall Response Rate at 3 months
Time Frame: Up to 3 months
|
The percentage of PR and CR patients in the total patient population at 3 months
|
Up to 3 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RJMty19-B-NHL002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on B-cell Non-Hodgkin's Lymphoma
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
Hoffmann-La RocheCompletedDiffuse Large B-Cell Lymphoma, Non-Hodgkin's LymphomaHong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Non-Hodgkin's Lymphoma | Intermediate Grade B-Cell Non-Hodgkin's LymphomaUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
Debiopharm International SACompletedDiffuse Large B-Cell Lymphoma | B-cell Non-Hodgkin's LymphomaUnited States, Czechia, Belgium, Hungary, Ukraine, Bulgaria, Italy, Poland, Switzerland
-
Eden BioCell Ltd.National Taiwan University HospitalTerminatedFollicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryTaiwan
-
Peking UniversityPeking University Cancer Hospital & InstituteRecruitingB Cell Non-Hodgkin's LymphomaChina
-
Peking UniversityUnknownB-cell Non-Hodgkin's Lymphoma
-
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Not yet recruitingB-cell Non-Hodgkin's Lymphoma
-
Second Affiliated Hospital, School of Medicine,...Zhejiang Ruijiamei Biotechnologies, Co., Ltd.RecruitingB-cell Non-Hodgkin's LymphomaChina
Clinical Trials on RJMty19 (CD19-CAR-DNT cells)
-
Second Affiliated Hospital, School of Medicine,...Zhejiang Ruijiamei Biotechnologies, Co., Ltd.RecruitingB-cell Non-Hodgkin's LymphomaChina
-
Guangdong Ruishun Biotech Co., LtdChanghai Hospital; Peking University People's Hospital; RenJi Hospital; The Affiliated...Not yet recruitingSystemic Lupus ErythematosusChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingNon-hodgkin Lymphoma,B CellChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingAcute Lymphoblastic Leukemia | Non-hodgkin Lymphoma,B CellChina
-
Miltenyi Biomedicine GmbHRecruitingB-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia RefractoryGermany
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingVasculitis | Amyloidosis | Autoimmune Hemolytic Anemia | POEMS SyndromeChina
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Zhejiang UniversityShanghai YaKe Biotechnology Ltd.Recruiting
-
University College, LondonEnrolling by invitationMultiple MyelomaUnited Kingdom
-
Miltenyi Biomedicine GmbHNot yet recruiting